[go: up one dir, main page]

ZA200706783B - Nanoparticulate formulations of docetaxel and analogues thereof - Google Patents

Nanoparticulate formulations of docetaxel and analogues thereof

Info

Publication number
ZA200706783B
ZA200706783B ZA200706783A ZA200706783A ZA200706783B ZA 200706783 B ZA200706783 B ZA 200706783B ZA 200706783 A ZA200706783 A ZA 200706783A ZA 200706783 A ZA200706783 A ZA 200706783A ZA 200706783 B ZA200706783 B ZA 200706783B
Authority
ZA
South Africa
Prior art keywords
docetaxel
analogues
nanoparticulate formulations
nanoparticulate
formulations
Prior art date
Application number
ZA200706783A
Other languages
English (en)
Inventor
Liversidge Gary
Jenkins Scott
Liversidge Elaine
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Publication of ZA200706783B publication Critical patent/ZA200706783B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA200706783A 2005-02-24 2007-08-15 Nanoparticulate formulations of docetaxel and analogues thereof ZA200706783B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65593405P 2005-02-24 2005-02-24

Publications (1)

Publication Number Publication Date
ZA200706783B true ZA200706783B (en) 2008-10-29

Family

ID=36928029

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200706783A ZA200706783B (en) 2005-02-24 2007-08-15 Nanoparticulate formulations of docetaxel and analogues thereof

Country Status (14)

Country Link
US (1) US20060188566A1 (xx)
EP (1) EP1855659A2 (xx)
JP (1) JP2008531591A (xx)
KR (1) KR20080003322A (xx)
CN (1) CN101160118A (xx)
AU (1) AU2006216640A1 (xx)
BR (1) BRPI0608173A2 (xx)
CA (1) CA2598441A1 (xx)
EA (1) EA015987B1 (xx)
IL (1) IL185292A0 (xx)
MX (1) MX2007010394A (xx)
NO (1) NO20074859L (xx)
WO (1) WO2006091780A2 (xx)
ZA (1) ZA200706783B (xx)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140070676A (ko) 2002-09-06 2014-06-10 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US20050232981A1 (en) * 2004-04-15 2005-10-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
US8034765B2 (en) * 2005-08-31 2011-10-11 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
HUE042678T2 (hu) * 2005-08-31 2019-07-29 Abraxis Bioscience Llc Vízben rosszul oldódó gyógyszerhatóanyagok és antimikrobiális szerek
CZ300305B6 (cs) * 2005-12-20 2009-04-15 Heaton, A. S. Farmaceutická kompozice obsahující derivát taxanu se zlepšenou terapeutickou úcinností
EP2343053A1 (en) * 2006-05-30 2011-07-13 Elan Pharma International Limited Nanoparticulate posaconazole formulations
EP2049084A2 (en) * 2006-07-10 2009-04-22 Elan Pharma International Limited Nanoparticulate sorafenib formulations
NZ549831A (en) * 2006-09-11 2009-03-31 Auckland Uniservices Ltd Combination of docetaxel and a nitrophenyl phosphate derivative for the treatment of cancer
WO2008066899A2 (en) * 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス, インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
WO2008092084A2 (en) * 2007-01-26 2008-07-31 Centocor, Inc. Injectable non-aqueous suspension with high concentration of therapeutic agent
WO2008118754A2 (en) * 2007-03-23 2008-10-02 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods for making the same
CN101677987A (zh) * 2007-06-22 2010-03-24 赛多斯有限责任公司 不含吐温80的多西他赛的增溶制剂
US9089544B2 (en) * 2007-08-24 2015-07-28 Slotervaart Participaties Bv Composition
AU2008291930B2 (en) * 2007-08-24 2014-04-17 Slotervaart Participaties Bv Compositions for the treatment of neoplastic diseases
WO2009047794A2 (en) * 2007-10-01 2009-04-16 Intas Pharmaceuticals Limited Taxane derivative composition
CN101909614B (zh) * 2007-12-24 2015-04-15 太阳医药高级研发有限公司 纳米分散体
KR101053780B1 (ko) * 2008-02-29 2011-08-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
AU2009234127B2 (en) * 2008-04-10 2015-04-30 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
WO2009126175A1 (en) * 2008-04-10 2009-10-15 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
HRP20170929T1 (hr) 2008-09-17 2017-09-22 Chiasma Inc. Farmaceutski pripravci i odgovarajući postupci za isporuku
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
EP2385824A2 (en) * 2009-01-06 2011-11-16 Pharmanova, Inc. Nanoparticle pharmaceutical formulations
EP3167875A1 (en) 2009-05-27 2017-05-17 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate meloxicam compositions
AU2010261342A1 (en) * 2009-06-19 2012-01-19 Sun Pharma Advanced Research Company Ltd., Nanodispersion of a drug and process for its preparation
KR101007925B1 (ko) * 2009-10-07 2011-01-14 건일제약 주식회사 경구용 지질 나노입자 및 그의 제조방법
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US20120225825A1 (en) * 2009-11-23 2012-09-06 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
FR2952936B1 (fr) * 2009-11-26 2011-11-25 Flamel Tech Polymere de type acrylique ou methacrylique comprenant des greffons alpha-tocopherol
CN101773480B (zh) * 2010-01-19 2012-03-14 山东大学 含有多西他赛的纳米结晶制剂及其冻干剂的制备方法
KR101894689B1 (ko) 2010-03-29 2018-09-04 아브락시스 바이오사이언스, 엘엘씨 암의 치료 방법
CA2794147A1 (en) * 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma
SG10201503234SA (en) 2010-05-03 2015-06-29 Teikoku Pharma Usa Inc Non-Aqueous Taxane Pro-Emulsion Formulations and Methods of Making and Using the Same
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
KR102154880B1 (ko) 2012-05-03 2020-09-10 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
JP6382187B2 (ja) * 2012-06-21 2018-08-29 フォスフォレックス,インコーポレーテッド インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
US9018246B2 (en) * 2012-09-05 2015-04-28 Lp Pharmaceutical (Xiamen) Co., Ltd. Transmucosal administration of taxanes
JO3685B1 (ar) * 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
CN103100087B (zh) * 2013-03-04 2014-09-10 中国科学院上海硅酸盐研究所 磷酸钙/有机物复合纳米颗粒的制备方法
KR20150123838A (ko) * 2013-03-04 2015-11-04 브이티브이 테라퓨틱스 엘엘씨 안정한 글루코키나제 활성화제 조성물
CN107823721B (zh) * 2013-05-02 2021-01-29 德国凯德诺有限责任公司 球囊表面涂层
CN105324484A (zh) * 2013-06-27 2016-02-10 那慕尔大学 混杂藻酸盐-二氧化硅珠粒及其获取方法
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
MX375742B (es) 2014-02-03 2025-03-06 Apurano Pharmaceuticals Gmbh Nanosuspension de materiales naturales y metodo de preparacion del mismo.
ES2763318T3 (es) * 2014-10-06 2020-05-28 Mayo Found Medical Education & Res Composiciones de vehículo-anticuerpo y procedimientos para preparar y usar las mismas
JP6706261B2 (ja) * 2014-12-01 2020-06-03 インノウプ、ファルマ、ソシエダッド、リミターダInnoup Farma, S.L. 化合物を封入するためのナノ粒子、その製造および使用
AU2016215350B2 (en) 2015-02-03 2021-11-25 Amryt Endo, Inc. Method of treating diseases
CA3026454C (en) 2015-06-04 2023-07-04 Crititech, Inc. Collection device and methods for use
CN114588270B (zh) 2015-09-16 2024-08-06 Dfb索里亚有限责任公司 包含紫杉烷类纳米颗粒的组合物及其用途
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
CN105581996B (zh) * 2016-02-23 2018-03-27 广西梧州制药(集团)股份有限公司 一种去水卫矛醇微囊及其制备方法
BR112018069628A2 (pt) * 2016-04-04 2019-02-12 Crititech, Inc. métodos para tratamento de tumor sólido
MX2019003943A (es) * 2016-10-05 2019-09-18 Univ Tohoku Farmaco eficaz para un metodo linfogeno de administracion de farmaco.
CN106588902B (zh) * 2016-11-29 2019-07-02 昌吉学院 一种紫杉醇抗癌药物、其制备方法及应用
EP3595633B1 (en) 2017-03-15 2023-07-05 DFB Soria, LLC Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
SG11201909840TA (en) 2017-06-09 2019-11-28 Crititech Inc Treatment of epithelial cysts by intracystic injection of antineoplastic particles
KR102303762B1 (ko) * 2017-06-14 2021-09-23 크리티테크, 인크. 폐 장애의 치료 방법
WO2019070850A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. LOCAL ADMINISTRATION OF ANINEOPLASTIC PARTICLES IN COMBINATION WITH SYSTEMIC DELIVERY OF IMMUNOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
US11497726B2 (en) 2018-03-16 2022-11-15 Dfb Soria, Ll. Topical therapy for the treatment of cervical intraepithelial neoplasia (CIN) and cervical cancer using nanoparticles of taxanes
WO2019200084A1 (en) * 2018-04-11 2019-10-17 Zhuhai Beihai Biotech Co., Ltd. Formulations and compositions of docetaxel
CN110292574A (zh) * 2019-08-02 2019-10-01 江苏红豆杉药业有限公司 一种抗肠癌药物组合物及其应用
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
EP4288060A4 (en) * 2022-04-14 2024-08-07 Wisdom Pharmaceutical Co., Ltd. PHARMACEUTICAL COMPOSITION AND INJECTION OF APREPITANT AND INJECTION OF LYOPHILIZED POWDER

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4638067A (en) * 1982-09-09 1987-01-20 Warner-Lambert Co. Antibacterial agents
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US5834025A (en) * 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US6153225A (en) * 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
DE69805860T2 (de) * 1998-08-21 2003-01-02 Pharmachemie B.V., Haarlem Wasserlösliche ähnliche verbindungen und medicament-vorstufe von paclitaxel
HK1042856B (zh) * 1998-11-20 2007-07-27 Skyepharma Canada Inc. 可分散的磷脂稳定的微粒
GB2355656B (en) * 1999-08-17 2004-04-07 Galena As Pharmaceutical compositions for oral and topical administration
AU2002214583A1 (en) * 2000-10-11 2002-04-22 Purdue Research Foundation Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof
KR100774366B1 (ko) * 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
DE60309300T3 (de) * 2002-03-20 2011-02-24 Elan Pharma International Ltd. Nanopartikelzusammensetzungen von angiogeneseinhibitoren
EP2283864A1 (en) * 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
EP1569620A4 (en) * 2002-10-30 2006-03-22 Spherics Inc NANOPARTICULAR BIOACTIVE AGENTS
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles

Also Published As

Publication number Publication date
EA015987B1 (ru) 2012-01-30
US20060188566A1 (en) 2006-08-24
BRPI0608173A2 (pt) 2010-11-09
AU2006216640A1 (en) 2006-08-31
EA200701793A1 (ru) 2008-02-28
KR20080003322A (ko) 2008-01-07
IL185292A0 (en) 2008-02-09
WO2006091780A2 (en) 2006-08-31
CA2598441A1 (en) 2006-08-31
JP2008531591A (ja) 2008-08-14
NO20074859L (no) 2007-11-26
CN101160118A (zh) 2008-04-09
MX2007010394A (es) 2008-02-19
WO2006091780A3 (en) 2007-01-11
EP1855659A2 (en) 2007-11-21

Similar Documents

Publication Publication Date Title
ZA200706783B (en) Nanoparticulate formulations of docetaxel and analogues thereof
IL186469A0 (en) Nanoparticulate and controlled release compositions comprising cyclosporine
IL185265A0 (en) Aerosol and injectable formulations of nanoparticulate benzodiazepine
IL184735A0 (en) Pharmaceutical formulations and methods of use
EP1804823A4 (en) NEW CYCLOSPORIN ANALOGUE AND ITS PHARMACEUTICAL APPLICATIONS
ZA200802501B (en) Indenoisoquinolinone analogs and methods of use thereof
IL199006A0 (en) Nanoparticulate formulations and methods for the making and use thereof
IL187957A0 (en) Liquid pharmaceutical formulations of docetaxel
ZA200708544B (en) Nanoparticulate corticosteroid and antihistamine formulations
IL189600A (en) Pharmaceutical preparation containing nanostarticles containing Dostaxel in anhydrous state
EP1909797A4 (en) DIPIPERAZINYL KETONE AND RELATED ANALOG
IL187842A0 (en) Nanoparticulate acetaminophen formulations
ZA200809971B (en) Nanoparticulate posaconazole formulations
EP2019664A4 (en) STABLE PHARMACEUTICAL COMPOSITION WITH DOCETAXEL AND METHOD FOR THE PRODUCTION THEREOF
PT1855652E (pt) Secagem de partículas contendo fármacos
IL202728A0 (en) Solubilized formulation of docetaxel without tween 80
EP1933863A4 (en) PARATHYROIDIAN HORMONE ANALOGS AND METHODS USING SAME
GB2443336B (en) Spiruchostatin analogues and their medicinal use
EP2261221A4 (en) EPOTHILONE ANALOGUES, THEIR PHARMACEUTICAL COMPOSITIONS, THEIR USE AND PREPARATIONS
EP2124897A4 (en) SPRAYING, ORAL, STABLE, SPRAY PREPARATIONS AND ASSOCIATED METHODS
EP1890677A4 (en) PHARMACEUTICAL COMPOSITIONS AND THEIR USE
EP1874731A4 (en) CHINOBENZOXAZINANALOGA AND METHOD FOR THE APPLICATION
FR2883743B1 (fr) Poudre et composition cosmetiques
ATE502682T1 (de) Zusammensetzung zur feuerbekämpfung und formulierungen aus dieser zusammensetzung
IL190583A0 (en) Pth formulations and methods of use